Meatable acquires cultivated meat platform from Uncommon Bio

NETHERLANDS – -Dutch cultivated pork producer Meatable is taking over the cultivated meat platform of UK-based Uncommon Bio, including technology, intellectual property, cell lines, and staff, while Uncommon pivots to work on medical therapies.

The acquisition comes as Meatable works toward regulatory approvals in different regions, aiming to widen its future foods portfolio and build capacity for expansion into multiple species.

According to Meatable’s chief technology officer Aris de Rijke, the deal provides flexibility beyond pork, which has been the company’s primary focus, by opening the possibility to develop beef, chicken, and other products.

Uncommon Bio, meanwhile, is turning its attention to the health sector, applying its existing non-GMO mRNA reprogramming and self-amplifying RNA differentiation technologies toward new treatments.

The company has indicated through job postings that it is pursuing therapies targeting several pathways simultaneously, with initial work directed at lung conditions such as idiopathic pulmonary fibrosis.

It has also described its polysaccharide-based delivery method as a scalable and safer approach for cell programming in multi-target therapies, setting the foundation for its move into medicine.

Uncommon Bio chief executive Benjamina Bollag said the company sought a suitable successor for its food technology and expressed confidence that Meatable will apply the platform at scale.

Meatable has built its production model on Opti-ox, a method that uses pluripotent stem cells, which naturally multiply and can quickly differentiate into muscle and fat tissue.

The company combines this with a perfusion system that enables high-density growth and completes the cycle from cells to meat components in about four days.

By adding Uncommon’s technology, Meatable plans to broaden its product range and adapt to different consumer markets and regulatory requirements.

De Rijke noted that the acquisition gives Meatable the ability to work with both GMO and non-GMO product lines, which is significant since non-GMO items may face fewer regulatory delays.

While pork and beef will remain central to Meatable’s work, the company has identified interest in other species, with chicken and lamb among the areas where Uncommon’s technology could be applied.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.